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Abstract  Regardless  of  the  advances  in  chemotherapy,  the  only  curative  treatment  for  colo-
rectal metastases  is  surgery,  which  must  be  complete  and  excise  all  of  the  metastatic  sites  of
disease. Thanks  to  advances  in  neoadjuvant  chemotherapy  and  also  to  alternative  techniques,
such as  radiofrequency  ablation,  however,  surgical  treatments  have  become  available  to  a  larger
number of  patients  and  have  improved  patient  survival.  The  aim  of  this  article  is  to  describe
the different  treatment  strategies  for  colorectal  metastases  and  to  examine  the  role  of  imagingmetastases in deﬁning  the  resect  ability  of  these  metastases.  The  key  factors  in  the  radiological  report  in
the initial  and  post-chemotherapy  assessments  are  described.
© 2014  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Metastases  from  colorectal  cancer  are  common  and  develop  in  40  to  60%  of  the  patients.
The  existence  of  metastases  classiﬁes  patients  into  M1  of  the  TNM  classiﬁcation  and  stage
IV  of  the  UICC/AJCC  classiﬁcation.  External  or  common  iliac  lymph  node  involvement  is
also  deemed  to  be  M1.
The  primary  metastatic  site  is  the  liver.  After  colorectal  cancer  has  developed,  40  to
50%  of  the  patients  will  develop  liver  metastases  and  synchronous  liver  metastases,  i.e.
those  present  at  the  time  when  the  colorectal  cancer  is  discovered  are  found  in  15  to
20%  of  the  cases.  The  cumulative  incidence  of  metachronic  liver  metastases,  i.e.  those
discovered  after  treatment  for  the  primary  tumor  is  around  15%  at  5  years.  The  risk  of
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• the  patient’s  background,  whether  it  is  compatible  with14  
eveloping  metastases  correlates  with  the  stage  of  the  pri-
ary  cancer  and  liver  invasion  is  also  a  major  prognostic
ndicator  and  therefore  a  major  treatment  challenge.  Whilst
iver  metastases  are  present  in  approximately  30%  of  all
atients  with  colorectal  cancer,  they  are  responsible  for
pproximately  2/3  of  the  deaths  [1].
The  other  sites  for  colorectal  cancer  metastases  are  rarer
nd  include  the  lungs,  peritoneum  and  pelvic  abdominal
ymph  nodes.  These  are  often  combined  with  liver  metas-
ases.
reatment strategies
reoperative  chemotherapy  has  become  a  standard  treat-
ent  in  the  initial  management  of  patients  with  metastases.
egardless  of  the  advances  in  chemotherapy,  however,  the
nly  curative  treatment  for  metastatic  colorectal  cancer
emains  surgery  for  the  primary  tumor  and  the  metastases.
his  surgery  must  be  complete  (R0),  excising  all  of  the
etastatic  disease  sites.  It  has  become  available  to  a  larger
umber  of  patients  because  of  advances  in  neoadjuvant
hemotherapy  and  in  surgery  and  also  as  a  result  of  alter-
ative  treatment  techniques,  particularly,  percutaneous
r  preoperative  ablation  therapy  techniques.  The  surgical
reatment  options  for  metastases  must  therefore  be  con-
idered  routinely  and  reassessed  throughout  the  patient’s
anagement.
hemotherapy
eoadjuvant  chemotherapy
he  purpose  and  choice  of  neoadjuvant  chemotherapy  vary
epending  on  the  possibilities  for  surgical  resection,  which
s  currently  the  only  curative  treatment  for  metastatic  colo-
ectal  cancer.  Its  purpose  is  to  reduce  the  risk  of  recurrence
nd  therefore  increase  overall  survival  in  metastatic  dis-
ase,  which  can  be  resected  from  the  outset,  to  make
he  patient  operable  by  obtaining  a  response  in  potentially
esectable  disease  and  to  increase  disease  free  survival  in
etastatic  disease,  which  has  ‘‘never’’  been  resectable.
Chemotherapy  in  metastatic  colorectal  cancer  has
hanged  greatly  in  recent  years  with  the  sequential  use
f  chemotherapy  with  oxaliplatin  (FOLFOX)  or  irinote-
an  (FOLFIRI),  which  have  doubled  median  survival  times,
ncreasing  from  11  months  to  approximately  21  months  [2,3].
urvival  has  also  recently  been  improved  by  the  introduction
f  new  pharmacological  agents,  particularly  the  biothera-
ies  and  with  the  identiﬁcation  of  predictive  indicators  for
reatment  response  or  failure.  The  addition  of  bevacuzimab
r  FOLFIRI  as  the  ﬁrst  line  treatment  increases  the  likelihood
f  objective  tumor  response  to  63%,  with  a  median  survival
f  28  months,  which  has  never  yet  been  achieved  in  this  sit-
ation  [4].  More  recently,  cetuximab,  an  epidermal  growth
actor  receptor,  (EGF-R  receptor)  combined  with  FOLFIRI,
as  also  achieved  an  overall  survival  of  23.5  months  [5]  in
rst  line  treatment  as  a  result  of  determining  the  tumor
RAS  status,  which  enables  a  group  to  be  selected  which
eneﬁts  from  this  treatment.
In  order  to  increase  the  resectability  of  metastases  (par-
icularly  liver),  it  is  now  possible  to  offer  selected  patients
•C.  Dromain  et  al.
 combination  of  3  cytotoxic  agents  and  a  biotherapy  with
evacizumab  or  cetuximab.  These  intensive  treatments  can
chieve  response  rates  of  over  70%  with  tumor  control  as
igh  as  100%  and  a  resectability  rate  of  approximately  70%,
lthough  this  is  at  the  cost  of  signiﬁcant  toxicity.
A  new  method  of  chemotherapy  administration  by  slow
ntravenous  hepatic  infusion  (SIHCA)  has  been  developed
o  treat  colorectal  metastases,  which  are  inoperable  from
he  outset  and  located  only  in  the  liver.  Hepatic  intra-
rterial  chemotherapy  requires  an  intra-arterial  catheter
o  be  introduced  either  by  laparotomy  or  percutaneously
y  radiology  and  uses  drugs,  which  have  a  high,  ﬁrst  pass
epatic  extraction  rate.  These  enable  higher  concentrations
o  be  achieved  within  the  tumor  and  therefore  a  better
esponse  to  treatment  than  the  same  chemotherapy  admin-
stered  systemically  (×5—10  for  5FU,  ×4 for  oxaliplatin
ompared  to  systemic  chemotherapy)  [6].  The  treatment
egimen  currently  used  is  a  combination  of  intra-arterial
hemotherapy  (5FU/FUDR,  irinotecan  or  oxaliplatin)  and
ystemic  chemotherapy,  which  achieves  particularly  high
esponse  rates  and  overall  survival  rates  ranging  from  74  to
2%  and  20  to  40  months,  respectively.  IHCA  has  also  been
hown  to  be  effective  in  patients  who  have  failed  treatment
fter  several  lines  of  systemic  chemotherapy  [7].  In  par-
icular,  the  use  of  oxaliplatin  IHCA  combined  with  LV5FU2
as  produced  response  rates  of  54%  in  patients  in  disease
rogression  after  treatment  with  systemic  oxaliplatin  [8].
ecause  of  the  high  response  rates  obtained,  this  type  of
reatment  is  indicated  particularly  in  patients  with  single,
otentially  resectable  liver  metastases.  A  recent  study  in  87
atients  with  liver  metastases  deemed  to  be  unresectable
nd  treated  with  IHCA  (oxaliplatin)  +  LV5FU2  reported  a
esectability  rate  of  26%  with  a  signiﬁcant  56%  gain  in  5-
ear  survival  compared  to  0%  in  the  group  of  patients  who
ere  not  treated  surgically  [9].  In  another  phase  II  study
the  CHOICE  study),  in  36  patients  treated  with  a  combi-
ation  of  intra-arterial  oxaliplatin  and  FU/LV  +  cetuximab,
he  response  rate  was  86%  with  a  resectability  rate  for  liver
etastases  of  48%  (ASCO  2010).
ostoperative  chemotherapy
he  purpose  of  postoperative  chemotherapy  is  to  reduce  the
ocal  recurrence  rate  and  to  increase  progression-free  sur-
ival  and  overall  survival  in  patients.  This  is  mostly  adjusted
n  terms  of  the  histological  response.  If  a good  histological
esponse  is  achieved,  it  is  standard  practice  to  repeat  the
ame  chemotherapy  as  was  used  preoperatively.
urgery
urgery  remains  the  only  curative  treatment  for  colorectal
ancer  metastases.  For  this  reason,  it  should  be  consid-
red  routinely  and  discussed  again  at  the  different  stages
n  patient  management  in  a  multidisciplinary  team  meet-
ng.  This  discussion  is  based  on  the  risk/beneﬁt  balance  of
urgery,  which  requires  the  following  criteria  to  be  assessed:anesthesia  and  resection  of  the  metastases;
oncological  restrictions:  the  total  absence  of  unresectable
tumor  sites;
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• anatomical  restrictions:  vascular  invasion,  sites  not
enabling  parenchyma  with  its  own  vascularization  to  be
left;
• technical  limitations:  the  ability  to  leave  a  sufﬁcient
residual  volume  in  situ;
• tumor  chemosensitization:  surgery  is  only  indicated  in
patients  who  respond  or  are  stable  after  chemother-
apy.  Progression  on  chemotherapy  is  a  contraindication
to  surgery  even  if  the  metastatic  lesions  appear  to  be
resectable.
Some  adverse  oncological  prognostic  criteria  (size  of
metastases  5  cm  or  over,  more  than  3  lesions,  bilobular  liver
disease,  invaded  pedicle  lymph  node,  raised  CEA)  may  be
included  in  the  decision  as  to  whether  or  not  to  operate.
These  however  are  not  contraindications  to  surgery  from
metastases.
The  indications  also  develop  on  the  number  and  site  of
the  metastases:
• a single  metastatic  site:  surgery  if  the  lesions  are
resectable;
• liver  +  lung:  sequential  surgery  for  lesions  are  resectable:
the  ﬁrst  excision  should  be  hepatic  followed  by  the  lung
resection  2  to  3  months  later.  Combined  sequential  exci-
sion  of  liver  and  lung  metastases  offers  a  5-year  life
expectancy  of  25  to  45%  at  5  years  [10];
• liver  +  peritoneum:  typically  this  is  a  contraindication  to
surgery  because  of  the  poor  prognosis  in  these  patients
although  excision  surgery  may  be  indicated  if  only  few
liver  metastases  are  present  (maximum  2  or  3)  and  are
easily  resectable.  If  the  peritoneal  metastatic  lesions
are  resectable  and  if  metastatic  disease  is  controlled  by
chemotherapy;
• liver  +  retroperitoneal  lymph  nodes:  this  is  a  contraindica-
tion  to  surgery.  Surgery  may  be  considered  if  the  disease
is  well  controlled  over  a  long  period;
• peritoneum  +  retroperitoneal  lymph  nodes:  this  is  a  con-
traindication  to  surgery;
• three  or  more  sites:  this  is  a  contraindication  to  surgery
regardless  of  whether  the  lesions  are  resectable.
Liver  surgery
Currently,  a  5-year  survival  after  surgery  ranges  from  37%  to
58%,  with  a  10-year  survival  rate  in  the  region  of  20%  to  25%.
Long-term  chemotherapy  undoubtedly  increases  short-  and
median-term  survival,  although  5-year  survival  if  surgery  is
not  carried  out  is  very  rare.  In  addition,  advances  in  postop-
erative  chemotherapy  have  greatly  increased  the  number
of  candidates  for  liver  surgery,  are  now  in  the  region  of
20  to  30%  (compared  to  approximately  3%  previously)  [11].
This  increase  in  the  number  of  patients  undergoing  surgery
correlates  clearly  with  the  increase  in  overall  survival.  It  is
recommended  that  if  possible  patients  are  operated  on  as
soon  as  the  metastases  become  resectable  without  waiting
for  more  than  4  months  after  chemotherapy,  as  the  maxi-
mum  reduction  in  tumor  burden  is  achieved  between  2  and
4  months  after  starting  treatment  and  by  leaving  a  period  4
to  6  weeks  after  completing  chemotherapy  before  surgery,
which  reduces  the  risk  of  complications.
The  deﬁnition  of  resectable  liver  metastases  has  changed
in  recent  years.  This  no  longer  takes  into  account  the  num-
ber  or  size  of  the  metastases  but  considers  the  excision  of
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ny  visible  metastasis,  which  allows  at  least  20  to  25%  of  the
emaining  liver  parenchyma  to  be  preserved  with  its  vascu-
ar  supply  and  biliary  drainage.  The  concept  of  resectability
aries  however  between  groups  depending  on  surgical  exper-
ise  and  interpretation  of  the  beneﬁt/risk  balance.  The
actors  which  impact  on  resectability  deﬁned  mostly  on
maging,  are  liver  function  (an  indocyanin  clearance  study),
he  technical  feasibility  of  surgery,  the  percentage  of  resid-
al  liver,  the  number  of  distant  metastatic  sites  and  their
esectability  and  the  response  to  chemotherapy  (surgery  is
ot  carried  out  on  a  patient  who  progresses  on  chemother-
py).
Three  types  of  liver  surgery  are  currently  carried  out:
simple  hepatectomies:  right  hepatectomy,  left  lobec-
tomy,  left  hepatectomy  and  right  hepatectomy  extended
to  segment  IV;
complex  hepatectomies:  central  hepatectomy  with  vas-
cular  exclusion,  enlarged  right  hepatectomy  (usually  to
segment  IV),  segmentectomies  and  vascular  reconstruc-
tion;
two  stage  hepatectomies  (Fig.  1)  involve  a  ‘‘cleaning’’  of
the  liver  lobe  or  lobes  to  remain  in  situ  by  tumorectomies
or  percutaneous  or  surgical  ablation  of  metastases  fol-
lowed  by  preoperative  vascular  ligation  or  contralateral
portal  embolization  to  hypertrophy  this  lobe  of  the  liver.
It  is  important  only  to  carry  out  portal  embolization  after
excision  of  lesions  in  the  lobe,  which  is  to  remain  in  situ
as  the  hepatic  ischemia  caused  by  embolization  leads  to
secretion  of  tumor  growth  factors,  which  could  promote
tumor  growth  and  make  the  lesions  unresectable.  Finally,
contralateral  hepatectomy  is  performed.
Two  stage  complex  hepatectomies  are  performed  in
xpert  centres.
ung  surgery
he  indications  for  this  are  the  same  as  for  liver  metas-
ases:  surgery  is  only  indicated  if  complete  excision  of
ll  metastases  is  possible  (‘‘wedge’’)  (metastasectomy  or
obectomy  after  thoracotomy  or  sternotomy).  Thoracotomy
ith  palpation  of  the  whole  lung  parenchyma  is  better  for
 detailed  staging  assessment.  Peroperative  chemotherapy
ay  be  used  in  the  same  way  as  for  liver  metastases.
eritoneal  surgery
s  applies  to  the  other  metastatic  sites,  surgery  is  the  only
urative  treatment  for  peritoneal  metastases.  This  involves
omplete  resection  of  the  lesions  followed  by  intraperi-
oneal  chemotherapy  (ICP)  ±  hyperthermia  (IPCH)  (Fig.  2),
hich  achieves  a  5-year  survival  rate  of  48.5%  and  median
urvival  of  60.1  months  [12]. Complete  surgical  cytore-
uction  is  required  before  administering  intraperitoneal
hemotherapy  as  the  tissue  penetration  of  chemotherapy
olecules  is  limited  to  a  few  cell  layers.  This  treatment  com-
ination  is  only  justiﬁed  if  all  lesions  over  2 mm  have  been
emoved.  The  chemotherapy  ‘‘bath’’  can  only  in  reality
reat  residual  disease  under  or  around  a  millimetre  in  size.
PCH  should  be  given  immediately  after  the  surgery  before
he  residual  tumor  cells  have  been  trapped  in  postoperative
dhesions.  These  adhesions  form  very  quickly  after  the  sur-
ical  injury  and  create  a  true  sanctuary  for  residual  tumor
516  C.  Dromain  et  al.
Figure 1. Liver metastases, which are potentially resectable by two stage hepatectomies. The CT appearances with contrast enhancement
over 4 section levels show relatively extensive liver lesions affecting the right lobe of the liver, segment 4 and the left lobe. The management
plan involves initially treating the left lobe liver metastases by radiofrequency ablation and then performing right portal embolization and
ﬁnally a right hepatectomy extending to segment 4.
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tigure 2. Surgical treatment of the peritoneal carcinomatosis inv
a) and intraperitoneal chemotherapy with hyperthermia (b).
ells.  IPCH  combines  the  effects  of  local  chemotherapy,
llowing  concentrations  at  least  25  times  greater  than  those
chieved  by  systemic  chemotherapy  with  those  of  hyper-
hermia,  which  potentiate  the  effect  of  the  chemotherapy.
h
p
p a combination of surgery with complete excision of the tumor sites
The  combination  of  cytoreduction  surgery  with  IPCH  is
owever  a  demanding  treatment  procedure,  which  is  com-
lex  and  long  (usually  lasting  more  than  6  h)  and  exposes  the
atient  to  high  risks  of  dying  and  postoperative  morbidity
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(0  to  9%  and  12  to  68%,  respectively)  and  because  this
requires  exceedingly  careful  patient  selection.  It  is  indi-
cated  if  the  carcinoma  is  isolated  and  extension  is  only
moderate  in  a  patient  in  good  general  health  without  organ
failure.  Criteria,  to  assess  whether  surgical  indication  +  IPCH
is  indicated,  are  currently  being  assessed  (Table  1)  [13]. The
main  factors  to  consider  are  those  relating  to  the  extent
of  cytoreduction  surgery  (duration,  number  of  anastamoses
to  be  created)  and  the  extent  of  intraperitoneal  extension.
In  addition  to  the  carcinoma  burden  the  main  limitation  to
R0  excision  is  the  disease  distribution  in  the  abdomen  and
pelvis,  which  is  best  assessed  from  the  Sugarbaker  Perit-
oneal  Index,  which  describes  extension  of  the  disease  into
each  region  of  the  abdomen  and  pelvis  and  also  into  the
small  intestine  and  colon.  This  index  is  more  accurate  than
the  Gilly  Index  [14,15].  The  score  (from  0  to  39)  assesses
the  resectability  of  peritoneal  carcinoma  lesions:  the  higher
the  score  the  more  extensive  resection  is  required  and  the
risk  of  death  or  postoperative  compilations  is  high.  It  is
widely  accepted  for  peritoneal  carcinomatosis  originating
from  colorectal  disease  with  an  index  of  over  20  is  a  con-
traindication  to  IPCH  as  the  likelihood  of  completely  excising
the  lesions  is  extremely  low.  In  addition,  some  sites  may
represent  contraindications  to  complete  excision.  These
include  mostly  the  small  intestine,  mesentery  (a  residual
length  of  at  least  2  m  is  required  for  satisfactory  quality  of
life),  the  stomach  and  the  left  gastric  blood  vessels.  Total
gastrectomy  with  IPCH  is  not  recommended  and  is  usually
combined  with  total  colectomy.  For  this  reason,  any  periton-
eal  carcinomatosis  found  during  laparotomy  or  laparoscopy
should  be  described  in  order  to  determine  whether  or  not
excision  is  possible  and  if  it  is,  at  what  cost.  In  order  to  assess
resectability,  surgeons  should  also  look  for  extra-peritoneal
contraindications,  particularly,  retroperitoneal  lymph  node
d
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Table  1  Criteria  to  assess  the  indication  for  surgery  (excisio
colorectal  cancer.
Major  exclusion  criteria  1.  Ag
med
2.  Ex
3.  Li
rese
4.  Pr
Minor  exclusion  criteria  1.  Ex
clini
2.  O
3.  O
4. C
carc
No  criteria  present  Indic
cent
is  no
One  minor  criterion  present  IPCH
advi
mad
One  major  criterion  or  2  minor  criteria  IPCH
mon
chem
More  than  one  major  criterion  or  3  minor  criteria  IPCH517
nvasion  and  more  than  3  not  ‘‘easily’’  resectable  liver
etastases  (Fig.  3).  Perioperative  chemotherapy  may  be
sed  in  the  same  way  as  for  liver  metastases.
lterative local treatments
he  development  of  local  percutaneous  or  peroperative
eat  ablation  therapies,  either  alone  or  in  combination  with
urgery,  has  increased  the  possibility  of  completely  excis-
ng  metastases,  particularly  when  two  stage  hepatectomies
re  indicated  and  for  combined  treatment  of  liver  and  lung
etastases  (Fig.  4).  These  treatments  are  still  indicated
or  tumors  under  3  cm  in  size.  If  hepatic  radiofrequency
blation  therapy  is  being  considered,  it  is  useful  to  per-
orm  a  liver  ultrasound  with  or  without  contrast  in  order
o  ensure  that  the  lesions  are  visible  on  ultrasound  and
hat  the  radiofrequency  ablation  can  be  ultrasound  guided
hether  it  is  carried  out  preoperatively  or  percutaneously.
hese  treatments,  however,  are  still  reserved  for  situations
hen  complete  surgical  excision  is  not  possible.  When  per-
ormed  alone,  they  do  not  enable  the  more  detailed  staging
ssessments  to  be  performed  which  surgery  offers  by  a
ull  investigation  of  the  abdominal  cavity  looking  for  car-
inomatosis  and  a  preoperative  ultrasound  to  examine  for
dditional  liver  lesions.
New  stereotactic  irradiation  techniques,  which  can
eliver  very  accurate  and  very  high  irradiation  doses  to
he  tumor  volume  on  a  non-invasive,  ambulatory  basis,  in  4
imensions  (with  respiratory  monitoring)  by  increasing  the
umber  of  beams,  are  currently  being  assessed.
The  indications  for  these  need  to  be  considered  in  a  mul-
idisciplinary  team  meeting  in  unresectable  patients.
n  +  IPCH)  for  peritoneal  carcinomatosis  originating  from
e  over  70  years  old  or  WHO2  or  more  or  serious  past
ical  history
tra-abdominal  metastases
ver  metastases  (except  if  <  3,  peripheral  and  easily
ctable)
ogression  on  systemic  chemotherapy
tensive  carcinomatosis  either  on  CT  or  with  major
cal  impact
besity  (BMI  >  40)
bstruction
oncomitant  intra-abdominal  metastases  other  than
inomatosis
ation  for  IPCH  →  patients  to  be  referred  to  a  reference
re.  If  synchronous  carcinomatosis  is  present,  colectomy
t  performed
 may  be  indicated  →  contact  a  reference  centre  for
ce  as  soon  as  the  diagnosis  of  carcinomatosis  has  been
e
 unlikely  to  be  indicated  →  repeat  in  assessment  at  three
ths  and  then  contact  a  centre  if  an  objective  response  to
otherapy  or  if  criteria  have  changed
 not  indicated  →  systemic  chemotherapy  if  possible
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Figure 3. Resectability assessment for liver metastases. The CT appearances centred on the liver (a, b, c) show 3 liver lesions, one of
which is located at the apex of the left lobe of the liver in contact with the left suprahepatic vein. The CT appearances in the abdomen (d,
e) show left ureteric dilatation stopping at a tissue nodule, which is suspicious of the peritoneal carcinomatosis. A PET CT (f) conﬁrmed that
this nodule was very suspicious in appearance. Surgery is contraindicated because of the combination of difﬁcult to resect liver metastases
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ind peritoneal carcinomatosis.
ole of imaging in the initial assessment
T, MRI and PET CT
he  initial  staging  assessment  is  essential  as  this  guides
he  treatment  strategy  by  classifying  the  metastatic  dis-
ase  into  disease,  which  is  resectable  from  the  outset,
otentially  resectable  or  ‘‘never’’  resectable.  The  initial
ssessment  should  be  optimal,  establishing  the  exact  num-
er  of  metastatic  sites  and  lesions  before  the  chemotherapy
i
d
bs  started.  This  assessment  is  also  the  key  factor  in  following
p  patients  after  treatment.
The  imaging  assessment  relies  on  chest  abdominal  and
elvic  CT,  always  including  portal  venous  phase  images  after
ontrast  enhancement  (70  s).
Abdominal  MRI  is  indicated  if  the  least  question  exists
n  order  to  improve  characterization  of  small  liver  lesions,
ncrease  the  sensitivity  of  detecting  some  poorly  reduced
ensity  metastases  on  CT  or  if  inconsistencies  are  found
etween  different  types  of  investigations  (particularly  CT
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Figure 4. Liver and lung metastases from a colorectal cancer. The CT appearances (a, b) show a subcapsular liver metastases in segment 6
and a lung metastasis. PET CT (c) was performed and conﬁrmed that no other lesions were present particularly in lymph node or peritoneum.
The treatment plan involves initially carrying out hepatic tumorectomy (or ‘‘wedge resection’’) followed by pulmonary radiofrequency
conse
aablation. The appearances of the postoperative CT (d, e) show the 
by the radiofrequency ablation.
ultrasound  and/or  FDG-PET  CT).  The  MRI  should  include
T2-weighted  images  (FSE/TSE)  and  phase  opposition  T1-
weighted  images  and  both  dynamic  and  effusion  weighted
images  (EG  3D)  after  contrast  [16].  Recent  chest  abdominal
c
pquences of hepatic tumorectomy and the area of necrosis induced
nd  pelvic  CT  techniques  with  diffusion-weighted  images  are
urrently  being  assessed.
FDG-PET  CT  is  useful  mostly  for  extra-hepatic  and  extra-
ulmonary  sites.  This  is  usually  recommended  if  metastases
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ppear  resectable  on  CT  from  the  outset  in  order  to  exclude
ther  metastatic  sites  and  also  to  conﬁrm  that  the  lesions
re  resectable.
ung  metastases
he  reference  investigation  is  CT.  This  should  provide  an
xhaustive  assessment  of  the  number,  sites  and  size  of  the
esions.  Its  main  difﬁculty  is  in  characterizing  small  lesions.
omparison  with  any  previous  CTs  is  extremely  useful.
iver  metastases
maging  should  provide  a  detailed  assessment  of  liver  metas-
ases  and  of  their  resectability.  The  assessment  should
etermine:
the  presence  and  site  of  any  concomitant  benign  lesions;
the  number  of  metastases:  this  is  a  prognostic  indicator
but  has  only  a  limited  inﬂuence  on  the  resectability  of
lesions  which  is  the  only  possibility  for  long-term  survival;
the  size  of  the  metastases:  the  percentage  of  liver
invaded  by  tumors  has  true  prognostic  value  rather  than
the  size  of  the  tumors  themselves.  Size,  however,  is  a
major  factor  in  assessing  the  possibility  of  heat  ablation
therapy  as  3  cm  is  deemed  to  be  the  critical  effectiveness
cut-off  for  radiofrequency  ablation  therapy;
the  site  of  metastases  by  vascular  territory:  right  lobe
of  the  liver,  segment  IV  and  left  lobe.  Subcapsular
metastases  can  be  treated  by  tumorectomy  (‘‘wedge’’
resection);
vascular  relationships  (portal  trunk  and  branches  and
hepatic  veins)  and  biliary  relationships  of  the  lesions;
the  volume  of  residual  liver  in  order  to  assess  the  need
for  preoperative  portal  embolization;
vascular  anatomical  variants  of  the  arterial  portal  and
hepatic  vein  branches.  The  presence  of  an  inferior  hepatic
vein  in  some  cases  enables  a  dual  V—VI  segmentectomy  to
be  performed  preserving  segments  VII  and  VIII.
If  necessary,  volumetry  of  the  healthy  and  diseased  liver
s  performed  to  assess  the  percentage  of  residual  liver  and
he  need  for  preoperative  portal  embolization.  Right  por-
al  embolization  is  recommended  if  right  hepatectomy  is
ndicated  and  the  percentage  of  residual  left  lobe  of  liver
s  under  25%  in  order  to  avoid  postoperative  hepatocellu-
ar  failure.  Embolization  should  be  performed  30  to  45  days
efore  the  hepatectomy.
eritoneal  metastases
T  is  still  the  reference  investigation  for  signs  of  periton-
al  carcinomatosis  although  its  sensitivity  for  tumor  sites
s  low  overall,  in  the  region  of  25  to  93%  and  there  is  poor
nter-observer  consistency  particularly  for  tumor  sites  under
 centimetre  in  size  [17—19].
FDG-PET  CT  is  recommended  as  an  addition  to  CT  if  per-
toneal  disease  is  suspected  or  when  excision  surgery  +  IPCH
s  indicated  in  order  to  increase  the  sensitivity  of  detec-
ing  tumor  sites  and  therefore  extension  of  the  peritoneal
isease.  Compared  to  CT,  PET  CT  has  the  advantage  of
reater  contrast  resolution  between  peritoneal  tumors  and
urrounding  structures  and  better  sensitivity  for  some  sites,
uch  as  the  mesentery,  loops  of  bowel  and  pelvis  [20].
onversely,  it  is  limited  by  its  spatial  resolution  which  is
p
T
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ver  5  mm,  possible  physiological  uptake  of  the  tracer  by
he  stomach  and  gastrointestinal  tract  causing  false-positive
esults,  movements  of  the  loops  of  bowel  during  the  acquisi-
ion  which  may  lead  to  underestimated  uptake  and  its  poor
ensitivity  in  the  right  hypochondrium  because  of  physiologi-
al  uptake  by  the  liver  parenchyma  and  for  some  histological
umor  types,  such  as  mucinous  adenocarcinomas,  which  take
p  contrast  very  weakly.
Abdominal  and  pelvic  MR  is  an  option  for  the  staging
ssessment  of  peritoneal  disease.  When  this  is  performed
ith  diffusion-weighted  images  using  sufﬁciently  higher  D
alues  (800  or  1000),  it  improves  the  sensitivity  for  tumor
ites  by  suppressing  the  signals  from  ascites,  gastrointesti-
al  ﬂuid  and  fat,  improving  the  sensitivity  of  detecting  some
natomical  sites  which  are  difﬁcult  to  assess  on  CT,  such  as
he  right  cupula  of  the  diaphragm,  the  loops  of  bowel  and  the
elvis  [21]. At  present,  however,  only  few  studies  have  been
erformed  in  colorectal  cancer,  which  have  been  analyzed
y  site  [20,22,23].
Regardless  of  the  type  of  imaging  used,  it  is  important  to
escribe  whether  or  not  peritoneal  carcinomatosis  is  present
nd  also  its  extension.  Extension  of  peritoneal  disease  is  one
f  the  major  prognostic  indicators  for  resectability  in  these
atients.  The  other  resectability  criteria  to  be  looked  for
n  imaging  are  the  presence  of  mesenteric  disease,  tumor
ites  in  contact  with  the  gastrointestinal  serosa  and  signs  of
bstruction  or  sub-acute  obstruction  (Table  1).
ole of imaging after neoadjuvant
hemotherapy
T and MRI
he  main  purpose  of  imaging  is  to  assess  the  response
o  chemotherapy  and  to  reassess  the  possibility  of  surgi-
al  resection.  This  assessment  should  be  compared  to  the
revious  CT  and  also  to  the  initial  assessment  before  the
hemotherapy  was  started.  It  should  include  a minimum  of
T  with  contrast  enhancement  in  the  portal  venous  phase
nd  it  is  often  useful  to  add  hepatic  MRI,  which  resolves
roblems  of  chemotherapy-induced  steatosis.  The  assess-
ent  should  again  describe  all  of  the  factors  described
bove  to  determine  whether  lesions  are  resectable.
etastases classiﬁed initially as resectable
rom the time of diagnosis
t  is  essential  to  conﬁrm  that  the  disease  has  not  progressed
r  that  new,  particularly,  extra-hepatic  lesions  have  not
eveloped.  FDG-PET  CT  is  a  useful  supplement  to  CT  and
epatic  MRI  in  this  situation  to  investigate  for  extra-hepatic
esions  before  surgery.  Conversely,  FDG-PET  CT  is  of  no  use
n  assessing  response  to  chemotherapy  for  liver  metastases
r  in  assessing  their  hepatic  resectability.
etastases classiﬁed initially as
otentially resectable
he  further  imaging  assessment  should  deﬁne  not  only
esponse  to  chemotherapy,  but  should  in  particular  assess
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whether  there  has  been  a  sufﬁcient  response  to  chemother-
apy  to  enable  the  metastases  to  be  resected.  It  is  also
essential  to  look  for  signs  of  chemotherapy  toxicity,  which
are  responsible  for  an  increase  in  per  and  perioperative
morbidity  and  mortality.  These  include  steatosis  and  steato-
hepatitis  and  vascular  lesions  including  the  sinus  occlusion
syndrome  (SOS  syndrome),  which  may  be  complicated  by
portal  hypertension  and  more  occasionally  by  regenerative
nodular  hyperplasia.  A  BMI  of  over  27  or  diabetes  increases
the  risk  of  steatohepatitis.
Some  metastases  disappear  completely  on  imaging  after
chemotherapy,  in  approximately  5%  of  the  patients  [24]. It  is
important  to  report  this  type  of  ‘‘missing  metastases’’  when
they  are  located  in  an  area  which  needs  to  be  preserved  dur-
ing  surgery.  These  lesions,  which  have  disappeared,  are  then
looked  for  carefully  peroperatively  by  ultrasound,  possibly
combined  with  contrast  enhancement.  It  has  been  shown
that  surgery  for  visible  lesions  leaving  lesions  which  have
disappeared  (including  those  which  have  disappeared  on
the  peroperative  ultrasound)  in  situ,  usually  combined  with
postoperative  intra-arterial  chemotherapy  achieves  a  5-year
survival  rate  of  40  to  80%  [25].  These  lesions  are  deemed  to
be  deﬁnitively  treated  in  62%  of  the  cases.
An  alternative  if  a  small  metastasis  on  the  initial  segment
is  located  in  a  segment  which  needs  to  be  preserved  during
planned  surgery  and  could  disappear  totally  after  neoad-
juvant  chemotherapy  is  to  place  an  ultrasound  guided  clip
within  the  lesion  before  beginning  treatment.  The  lesion  can
therefore  be  easily  identiﬁed  during  surgery.
Metastases classiﬁed initially as never
resectable
Imaging  assesses  the  response  to  chemotherapy  according
to  the  RECIST  1.1  criteria.  A  vascular  response  should  also
be  looked  for  if  targeted  therapy  has  been  used.
FDG-PET  CT  has  no  recognized  beneﬁt  in  assessing
response  to  chemotherapy  for  colorectal  metastases.
TAKE-HOME  MESSAGES
Treatment  strategy
• The  treatment  of  metastatic  colorectal  cancer  has
become  a  complex  strategic  problem,  with  many
advances,  which  have  resulted  in  improved  patient
survival  and  increasing  number  of  patients  treated
curatively.
• Many  treatment  options  have  emerged  and  the
multidisciplinary  team  meetings  therefore  play
an  essential  role  in  determining  the  appropriate
treatment  for  each  patient.  We  should  not  forget
that  despite  the  recent  advances  in  chemotherapies
and  the  arrival  of  the  targeted  biotherapies,  that
surgical  resection  offers  the  only  possibility  of  a  cure.
• The  indication  for  surgery  is  based  on  an  assessment
of  the  beneﬁt/risk  balance  and  requires  assessment
of  the  patient’s  underlying  condition,  the  number
of  metastatic  sites,  anatomical  and  technical 1521
limitations  (blood  vessels,  residual  volume)  and
chemosensitivity  of  the  tumors.  Progression  on
chemotherapy  is  a  contraindication  to  surgery.
• If  several  metastatic  sites  are  present,  sequential
liver  +  lung  surgery  is  possible  if  the  lesions  are
all  resectable.  Liver  +  peritoneal  disease  is  usually
a  contraindication  (except  when  fewer  than  3
easily  resectable  liver  metastases  are  present).
Liver  +  lymph  node  disease  or  disease  involving  3  or
more  sites  is  a  contraindication  to  surgery,  regardless
of  whether  the  lesions  are  resectable.
The  role  of  imaging
• Excellent  quality  imaging  is  essential  at  all  stages
of  managing  colorectal  metastases  (diagnosis,
assessment  and  postoperative  follow  up,  assessment
of  response  to  chemotherapy,  etc.).  Its  primary
objective  is  to  evaluate  and  reassess  the
respectability  of  lesions  at  the  different  stages
of  patient  management.  This  requires  a  full  detailed
imaging  assessment  with  exhaustive  mapping  of  the
patient’s  metastatic  disease.
• Imaging  is  based  above  all  on  hepatic  contrast-
enhanced  CT  and  MRI  and  should  be  repeated  at
each  stage  of  patient  management.  FDG-PET  CT  is
mostly  useful  preoperatively  to  investigate  for  extra-
hepatic  and  extra-pulmonary  sites  of  disease,  which
would  be  contradictory  to  surgery.
• If liver  metastases  are  present,  their  number  and
size  (this  is  more  of  prognostic  value  than  of  value
to  determine  resectability,  the  site  by  vascular
territory,  vascular  relationships,  the  volume  of
residual  liver  and  any  anatomic  vascular  variants)
should  be  established.
• If peritoneal  disease  is  present  the  distribution  of
tumor  sites  within  the  abdominal  and  peritoneal
cavity  should  be  described,  including  a  description
of  whether  mesenteric  and  bowel  loop  disease  is
present.
linical case
his  59-year-old  female  patient  is  being  followed-up  for  late
etastases  of  a  colonic  cancer  treated  surgically  18  months
go.  A  chest,  abdominal  and  pelvic  CT  showed  no  abnormal-
ties  apart  from  liver  metastases  and  a  complimentary  liver
R  was  performed  (Fig.  5).
uestion
.  Describe  the  appearances  as  in  a  full  imaging  report.
.  Are  the  lesions  resectable  or  not?  Justify  your  answer.
.  What  type  of  treatment  would  you  propose?
nswers.  The  T2-weighted  images  (Fig.  5a—b)  show  3  lesions  sug-
gestive  of  metastases:  a  lesion  approximately  40  mm  in
size  in  segment  VIII  adhering  to  the  right  hepatic  vein,  a
522  C.  Dromain  et  al.
F se op
2
3igure 5. T2-weighted images (a, b), T1 phase image (c), T1 pha
lesion  in  segment  V,  a  lesion  and  small  centimeter  size
lesion  in  the  left  lobe  of  the  liver.  The  phase  (Fig.  5c)  and
phased  opposition  (Fig.  5d)  T1-weighted  images  show  a
large  fall  in  non-tumor  liver  parenchymal  signal  in  phase
opposition,  indicating  diffuse  hepatic  steatosis,  which  is
slightly  heterogeneous.  The  patient  is  also  considerably
overweight.  The  contrast-enhanced  image  in  the  venous
phase  (Fig.  5e)  shows  an  accessory  right  inferior  hepatic
vein.
.  The  patient  has  bilobar  metastases  although  there  are
few  of  these  and  they  are  small  apart  from  the  lesion  in
the  dome  of  the  right  side  of  the  liver.  A  single  lesion  is
present  in  the  left  lobe:  this  is  small  in  size  and  locatedposition image (d), enhanced T1 image in the venous phase (e).
beneath  the  capsule  and  as  a  result  tumorectomy  or
radiofrequency  ablation  therapy  can  be  considered.  The
metastases  are  therefore  resectable  from  the  outset.
.  Surgery  should  therefore  be  offered  for  the  liver  metas-
tases  in  the  absence  of  extra-hepatic  metastases.  The
existence  of  overweight  and  hepatic  steatosis  increases
the  morbidity  of  hepatectomy  and  should  encourage
surgery  to  be  as  conservative  as  possible.  The  presence
of  an  accessory  inferior  right  hepatic  vein  enables  a  VII
and  VIII  bi-segmentectomy  to  be  considered,  leaving  seg-
ments  V  and  VI  in  situ.  The  metastases  in  segment  V  and
the  left  lobe  are  less  than  3  cm  in  size  and  should  be
treated  by  peroperative  radiofrequency  ablation.
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